IncellDx

IncellDx HPV OncoTect 3Dx system combines the quantification of oncogene mRNA overexpression, proliferation, and aneuploidy in one high-throughput assay, according to the firm.

The deal covers IncellDx's portfolio of immune-oncology and oncology diagnostic products including its single-cell assay for quantifying PD-L1 on tumor cells and immune cell subtypes.

The companies said they plan to develop a number of tests, beginning with a CTC-based PD-L1 assay that measures both RNA and protein expression.

The deal covers IncellDx's portfolio of immune-oncology & oncology diagnostic products including its single-cell assay for quantifying PD-L1 on tumor cells & immune cell subtypes.

The two companies intend to develop and commercialize several cancer and NIPT assays using a combination of their technologies.

The deal covers IncellDx's single-cell immune-oncology and oncology diagnostic products including its single-cell PD-L1 assay.

The companies will study the combination of their respective technologies for predicting patient responses to metastatic lung cancer immunotherapy.

The kit uses a proprietary non-enzymatic method to prepare intact, single-cell suspensions from tissue in less than 10 minutes.

Pages

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.

In Science this week: reduction in bee phylogenetic diversity, and more.